Scancell's amazing rise continues - UPDATE

Scancell, the developer of therapeutic cancer vaccines, continued its amazing price rise in early morning trade on Monday to become a 10-bagger in only a few months.

It has apparently been propelled by hopes its news technology platform for anti-cancer vaccines, called Moditope, will be able to successfully produce an anti-cancer vaccine that destroys tumours without toxicity.

David Lowery, equity analyst at Faraday Research told Digital Look that the development was "potentially ground-breaking" and that "If the discovery is as big as it sounds the shares are potentially worth several pounds."

Article continues below

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Canny investor David Newton, from the Helium Special Situations fund, has been a long term holder of the company and has a stake of 6.88%.

In mid-morning trade the shares stood at 59.5p, up 16.67% on the day. The share price is now 80% higher over the past month and up a whopping 1,000% over the last year.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.